Canada markets closed

Defence Therapeutics Inc. (DTC.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
6.300.00 (0.00%)
At close: 9:57AM EDT
Full screen
Previous Close6.30
Open6.34
Bid6.25 x N/A
Ask6.30 x N/A
Day's Range6.30 - 6.34
52 Week Range2.56 - 7.85
Volume300
Avg. Volume21,024
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants
    Newsfile

    The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants

    Vancouver, British Columbia--(Newsfile Corp. - July 6, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce, as an update of it's May 31st, 2021 press release, that sera isolated from AccuVAC-PT001-vaccinated animals cross-reacts with the Spike protein of several SARS-CoV-2 variants. More specifically, generated antibodies bind the RBD domains (responsible for bindi

  • Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer
    Newsfile

    Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer

    Vancouver, British Columbia--(Newsfile Corp. - June 29, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased to announce the establishment of a collaboration with the Curie Institute (Paris, France) to evaluate the therapeutic efficacy of Accum-T-DM1 ADC in patient-derived xenograft (PDX) models of breast cancer. The Curie Institute is a worldwide renowned center engaged leader in fundamental and applied scientific research to better serve humankind in fighting i

  • Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties
    Newsfile

    Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties

    Vancouver, British Columbia--(Newsfile Corp. - June 22, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased to announce major breakthrough advances in its pre-clinical research program on its AccuTOX (free AccumTM or AccumTM variants) molecules as potent anti-cancer agents. The AccumTM technology platform is very efficient at enhancing intracellular delivery of proteins of pharmacological interests such as ADCs or vaccine antigens. Defence's scientific team rece